Mayur Saxena, CEO of Droice Labs, chaired a panel discussion at DIA Global on June 18, 2024 where industry leaders from Abbvie, Amgen, AstraZeneca, and Bayer discussed how to use real-world data (RWD) in clinical trials in such a way that it can be relied upon as core evidence for regulatory decisions, including external control arms (ECAs), hybrid or pragmatic clinical trials, and RWD powered covariate adjustment. Sign up below to receive a summary of the discussion.
Droice Labs’ mission is to reduce the size and duration of clinical trials by using real-world evidence (RWE). Droice’s technologies scalably convert raw, messy real-world patient data (RWD) collected in routine care (e.g. EHRs, labs, claims etc.) into high quality, reliable data for biopharma clinical trials as per FDA guidance. Furthermore, Droice has developed methodologies that leverage this high quality, reliable RWD to increase statistical power in clinical trials. Droice’s technologies and approaches solve the scalability and data reliability issues that have traditionally been a bottleneck for leveraging RWD to accelerate clinical trials. Droice Labs has been working with several pharma and US/European hospital partners to generate reliable RWD at scale to increase the speed and efficiency of clinical trials.
Sign up to receive the summary:
